Navigation Links
Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations
Date:10/28/2010

$0.61 per diluted share, in the first nine months of 2009.

"The company's results for the third quarter and year-to-date 2010 reflect our success at delivering solid financial results while we continue to execute on our market and product development strategies designed to generate sustained growth for Thoratec over the long term," noted Gary F. Burbach, president and chief executive officer of Thoratec.

"Our top line performance was driven by the continued worldwide adoption of the HeartMate II® LVAS (Left Ventricular Assist System) for Bridge-to-Transplantation (BTT) and Destination Therapy (DT). At the same time, we continued to achieve solid operating leverage as reflected by our earnings performance."

The company indicated that it ended the quarter with 242 HeartMate II centers globally, an increase of 31 centers through the first nine months of 2010, with 181 centers worldwide now utilizing its new HeartMate peripherals, which are providing important quality of life benefits to patients and generating incremental revenue growth.

"Helping to drive our near-term financial performance and market leadership position for the future are investments in our field organization and market development programs that are generating referral activity among cardiologists, while providing centers support in areas including reimbursement and clinical best practices," Burbach said.

Burbach noted that the FDA has approved a label change for the HeartMate II incorporating the data from the company's BTT post-approval study that showed survival of 90 percent at six months and 85 percent at one year. "The outcomes from this study also reflected continued improvements in several important adverse event categories among HeartMate II patients, including zero device replacements and lower reported rates of bleeding, stroke and right heart failure," he commented.

"In addition, we continue to see the release of favorable HeartMate II data
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... LOS ANGELES--(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Urological,Association (AUA) Annual Meeting, which is currently taking ... Dr. Timothy A.,Yap from the Cancer Research UK ...
... WIRE)--May 21, 2007 - Medical,professionals seeking to ... gram-negative pneumonia may have a new weapon:,NKTR-061 ... by Nektar Therapeutics (Nasdaq:NKTR)., Results of a ... of,NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated,patients ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... its popular VitaSkin™ collection of products, the VitaSkin™ Exfoliating Peels. This revolutionary collection ... VitaSkin™ pillars: Firm, Bright, Calm, and Clear. , Formulated with alpha hydroxy ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It is ... alliance is dedicated to the provision of quality addiction treatment and the ...
(Date:9/1/2015)... California (PRWEB) , ... September 01, 2015 , ... ... Arrowsmith interviewed dating men and pick-up artists about their experiences of female beauty, ... men’s bodily concerns, including penis issues, as well as their relationships with other ...
(Date:9/1/2015)... ... September 01, 2015 , ... Routines… every family has them. Whether ... make things easier for parents, caregivers and children too. Here are three reasons why ... and small become more fluid. When a routine is implemented into a child’s schedule, ...
(Date:9/1/2015)... ... ... September is Baby Safety Month, and Lightning Labels wants to ... ones' safety top of mind at all times. , Sponsored by the Juvenile Products ... JPMA's Baby Safety Zone website, this year's theme is A Room with A Safe ...
Breaking Medicine News(10 mins):Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3
... STANFORD, Calif. Researchers at the Stanford University School ... three-dimensional cancers in a tissue culture dish for the ... divide and invade surrounding tissue will help physicians better ... new technique also provides a way to quickly and ...
... ,Kidney Donations by the Poor Are on the Decline ... incomes are more likely to develop kidney failure and less ... of other socioeconomic classes. Because fewer individuals in the U.S. ... of British Columbia, in Vancouver, Canada) and colleagues examined trends ...
... HealthDay Reporter , FRIDAY, Nov. 19 (HealthDay News) ... relax and have a drink a two, but they also ... studies show. The researchers found that fears about moderate ... about weight are not. Both studies, conducted by different ...
... November 19, 2010 - Data presented today from a ... recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) ... of life scores compared to best standard of care ... of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the ...
... pinworm medicine is a new lead in the search for ... The findings, reported by Vanderbilt University Medical Center researchers in ... a fresh approach for developing therapeutics that target the pathway. ... the second deadliest type of cancer in the developed world ...
... construct an online interactive world map which gives stark facts ... and following the birth of their child. Social scientists ... collaboration with the White Ribbon Alliance for Safe Motherhood and ... excess of 160,000 called ,The Atlas of Birth, which also ...
Cached Medicine News:Health News:Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes 2Health News:Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes 3Health News:Efforts needed to address disparities in kidney transplantation 2Health News:Efforts needed to address disparities in kidney transplantation 3Health News:Efforts needed to address disparities in kidney transplantation 4Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 2Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 3Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 4Health News:Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting 2Health News:Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting 3Health News:New path for colon cancer drug discovery 2Health News:Online map of maternal health to inform world leaders 2